Loading company…
SurgeCare uses blood-based testing to predict patients' risk of complications after surgery.
Founded in 2021 and based in Illkirch-Graffenstaden, SurgeCare develops an AI-based test that analyzes immune signals in pre-surgery blood samples to predict postoperative risk. In March 2024, it raised EUR 7.5 million in venture funding led by Eurazeo, with Kima Ventures, Teampact Ventures, Malakoff Humanis Investissements Privés, MH Innov, and returning investors participating. The company planned to launch a laboratory, refine its algorithm, and commercialize its PreCyte test.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in